EyePoint Inc
EYPT
Company Profile
Business description
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Contact
480 Pleasant Street
Suite C-400
WatertownMA02472
USAT: +1 833 393-7646
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
214
Stocks News & Analysis
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,745.30 | 66.70 | 0.77% |
| CAC 40 | 7,825.66 | 81.74 | 1.06% |
| DAX 40 | 22,905.97 | 269.06 | 1.19% |
| Dow JONES (US) | 46,435.09 | 311.03 | 0.67% |
| FTSE 100 | 10,080.89 | 115.73 | 1.16% |
| HKSE | 25,335.95 | 272.24 | 1.09% |
| NASDAQ | 21,947.40 | 185.50 | 0.85% |
| Nikkei 225 | 53,749.62 | 1,497.34 | 2.87% |
| NZX 50 Index | 12,929.30 | 227.55 | 1.79% |
| S&P 500 | 6,596.49 | 40.12 | 0.61% |
| S&P/ASX 200 | 8,534.30 | 45.70 | 0.54% |
| SSE Composite Index | 3,931.84 | 50.56 | 1.30% |